Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Trialing targeted therapies for autism

    Access options

    Rent or Buy article

    Get time limited or full article access on ReadCube.

    from$8.99

    All prices are NET prices.

    References

    1. 1

      Henderson, C. et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci. Transl. Med. 4, 152ra128 (2012).

      Article  Google Scholar 

    2. 2

      Berry-Kravis, E.M. et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci. Transl. Med. 4, 152ra127 (2012).

      Article  Google Scholar 

    3. 3

      Krueger, D.D. & Bear, M.F. Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu. Rev. Med. 62, 411–429 (2011).

      CAS  Article  Google Scholar 

    4. 4

      Jacquemont, S. et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci. Transl. Med. 3, 64ra61 (2011).

      Article  Google Scholar 

    5. 5

      Soden, M.E. & Chen, L. Fragile X protein FMRP is required for homeostatic plasticity and regulation of synaptic strength by retinoic acid. J. Neurosci. 30, 16910–16921 (2010).

      CAS  Article  Google Scholar 

    6. 6

      Hall, S.S., Hammond, J.L., Hirt, M. & Reiss, A.L. A. 'learning platform' approach to outcome measurement in fragile X syndrome: a preliminary psychometric study. J. Intellect. Disabil. Res. 56, 947–960 (2012).

      CAS  Article  Google Scholar 

    7. 7

      Guy, J., Gan, J., Selfridge, J., Cobb, S. & Bird, A. Reversal of neurological defects in a mouse model of Rett syndrome. Science 23, 1143–1147 (2007).

      Article  Google Scholar 

    8. 8

      Bear, M.F., Huber, K.M. & Warren, S.T. The mGluR theory of fragile X mental retardation. Trends in Neurosci. 27, 370–377 (2004).

      CAS  Article  Google Scholar 

    9. 9

      Katz, D.M., et al. Preclinical research in Rett syndrome: setting the foundation for translational success. Dis. Model Mech. 5, 733–745 (2012).

      CAS  Article  Google Scholar 

    10. 10

      Ecker, C., Spooren, W. & Murphy, D.G. Translational approaches to the biology of Autism: false dawn or a new era? Mol. Psychiatry published online, 10.1038/mp.2012.102 (17 July 2012).

    11. 11

      Mendez, M.A. et al. The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)C]Ro15–4513 positron emission tomography study. Neuropharmacology published online, 10.1016/j.neuropharm.2012.04.008 (21 April 2012).

    12. 12

      Ecker, C. et al. Describing the brain in autism in five dimensions–magnetic resonance imaging-assisted diagnosis of autism spectrum disorder using a multiparameter classification approach. J. Neurosci. 30, 10612–10623 (2010).

      CAS  Article  Google Scholar 

    Download references

    Ethics declarations

    Competing interests

    The authors declare no conflict of interest.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Trialing targeted therapies for autism. Nat Med 18, 1746–1747 (2012). https://doi.org/10.1038/nm.3027

    Download citation

    Search

    Quick links

    Nature Briefing

    Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

    Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing